

Supplementary Table 1. Baseline characteristics between included and excluded patients at 1 year

Variable	Excluded (n = 9,542)	Included (n = 5,389)	p value
Age (yr)	63.10 ± 12.15	61.91 ± 11.78	< 0.001
Male	7,428 (77.8)	4,275 (79.3)	0.036
Clinical presentation as STEMI (%)	4,815 (50.5)	2,913 (54.1)	< 0.001
hs-CRP (mg/L)	11.56 ± 30.03	11.63 ± 28.40	0.894
Killip classification III/IV	877 (9.5)	568 (10.5)	0.037
Hypertension	4,727 (49.5)	2,606 (48.4)	0.171
Diabetes mellitus	2,597 (27.2)	1,346 (25.0)	0.003
Dyslipidemia	1,379 (14.5)	908 (16.8)	< 0.001
BMI (kg/m ²)	24.38 ± 3.26	24.41 ± 3.29	0.532
Previous MI	672 (7.0)	286 (5.3)	< 0.001
Previous angina	809 (8.5)	351 (6.5)	< 0.001
Previous HF	101 (1.1)	47 (0.9)	0.309
Previous stroke	562 (5.9)	313 (5.8)	0.867
Current smoking	3,873 (40.6)	2,266 (42.0)	0.085
LVEF (%)	52.65 ± 10.53	52.54 ± 10.44	0.547
WBC (10 ³ /μL)	10.22 ± 3.77	10.32 ± 3.69	0.100
Hb (g/dL)	14.08 ± 1.96	14.19 ± 1.92	0.001
Platelet (10 ³ /μL)	235.20 ± 76.93	236.37 ± 65.12	0.349
Glucose (mg/dL)	165.97 ± 74.96	159.99 ± 69.01	< 0.001
Creatinine (mg/dL)	1.08 ± 0.95	1.06 ± 1.07	0.431
eGFR (mL/min/1.73 m ²)	81.76 ± 39.95	83.30 ± 34.85	0.018
CK (μg/L)	822.38 ± 1,405.67	1,237.74 ± 1,943.57	< 0.001
CK-MB (ng/mL)	110.80 ± 144.60	131.42 ± 170.58	< 0.001
TnI (ng/mL)	44.92 ± 91.42	43.51 ± 103.81	0.476
TC (mg/dL)	179.43 ± 45.47	181.48 ± 44.87	0.011
TG (mg/dL)	143.41 ± 111.37	146.41 ± 113.82	0.132
HDL-C (mg/dL)	43.11 ± 11.68	43.75 ± 11.74	0.002
LDL-C (mg/dL)	112.82 ± 38.57	113.21 ± 39.19	0.579
NT-proBNP (pg/mL)	1,786.65 ± 6,922.00	1,518.77 ± 5,027.50	0.066
BNP (pg/mL)	110.97 ± 455.73	66.11 ± 283.07	0.001
HbA1c (%)	6.48 ± 1.41	6.37 ± 1.35	< 0.001
IRA			0.082
Left main	239 (2.5)	115 (2.1)	
LAD	4,521 (47.4)	2,479 (46.0)	
LCX	1,619 (17.0)	981 (18.2)	
RCA	3,163 (33.1)	1,814 (33.7)	
Multivessel PCI	1,493 (15.6)	793 (14.7)	0.135
PreTIMI 0/1	5,430 (57.6)	3,204 (59.8)	0.008
PostTIMI 3	9,299 (97.5)	5,205 (96.6)	0.003

Supplementary Table 1. Continued

Variable	Excluded (n = 9,542)	Included (n = 5,389)	p value
ACC/AHA type B2/C lesion	8,031 (85.7)	4,421 (83.6)	0.001
Aspirin	9,526 (99.8)	5,378 (99.8)	0.762
Clopidogrel	6,309 (66.1)	3,163 (58.7)	< 0.001
PotentP2Y12	4,626 (48.5)	2,917 (54.1)	< 0.001
Cilostazol	660 (6.9)	330 (6.1)	0.066
Calcium channel blocker	746 (7.8)	332 (6.2)	< 0.001
B-blocker	7,916 (83.0)	4,526 (84.0)	0.111
RAASi	7,311 (76.6)	4,254 (78.9)	0.001
Statins	9,115 (95.5)	5,200 (96.5)	0.005
Oral anticoagulation	343 (3.6)	183 (3.4)	0.557

Values are presented as mean ± standard deviation, number (%), or median [interquartile range].

STEMI, ST-segment elevation myocardial infarction; hs-CRP, high-sensitivity C-reactive protein; BMI, body mass index; MI, myocardial infarction; HF, heart failure; LVEF, left ventricular ejection fraction; WBC, white blood cell count; Hb, hemoglobin; eGFR, estimated glomerular filtration rate; CK-MB, creatine kinase–MB isoenzyme; TnI, troponin-I; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NT-proBNP, N-terminal pro-B-type natriuretic peptide; HbA1c, glycated hemoglobin; IRA, infarct-related artery; LAD, left anterior descending artery; LCX, left circumflex artery; RCA, right coronary artery; PCI, percutaneous coronary intervention; TIMI, thrombolysis in myocardial infarction; ACC/AHA, American College of Cardiology/American Heart Association; RAASi, renin–angiotensin–aldosterone system inhibitor.